基本信息
views: 33
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Steven Badman is a clinically-trained public health researcher with over 10 years of experience in point-of-care testing for the detection and treatment of viral and sexually transmissible infections (STIs) in high-burden, low-resource settings.
From 3 January 2022, he will commence a new role as the Director of Medical and Scientific Affairs for the APAC region (Cepheid).
While at the Kirby Institute at UNSW Sydney from 2013-2021 he led multi-disciplinary field research teams in Fiji, Myanmar, Papua New Guinea (PNG), Vanuatu, and rural and remote communities in Australia. He has led international public health projects in Indonesia, Malaysia, and Thailand.
Dr Badman has been an investigator on a series of trials as a point of care specialist. His expertise includes trial design, planning, implementation science, and evaluation. Quality control (QC) and external quality assurance (EQA) are two additional areas that he supervises within clinical trials. In 2014-15 he was a lead investigator in a world-first field evaluation of a novel HPV-based cervical screening strategy among 1000 women in PNG. In this study, point-of-care HPV-DNA testing using self-collected specimens outperformed visual inspection of the cervix with acetic acid (VIA), or a combination of HPV testing plus VIA, for the detection and treatment of underlying high-grade cervical disease.
In 2020 this team completed an NHMRC-funded field trial among 3400 women in PNG (ISRCTN13476702) to confirm these initial findings, and the cost-effectiveness, health system implementation requirements, and acceptability of this innovative ‘test and treat’ model. As a co-investigator, he is currently involved in a cluster-randomized crossover trial of antenatal point-of-care testing and treatment of sexually transmitted infections (STI) to improve birth outcomes in high-burden, low-resource settings (ISRCTN37134032).
This world-first trial is funded by a Joint Global Health Trials award (MR/N006089/1) and builds on earlier research that demonstrated the poor performance of the 'syndromic' STI management approach (based on clinical features alone without laboratory confirmation) in this setting. The trial is being conducted among 4600 antenatal women and their newborns in PNG and will be the largest clinical trial ever conducted in this setting. Dr Badman was a lead investigator on a recently completed NHMRC stepped-wedge cluster-randomized trial of point-of-care testing for early infant diagnosis of HIV in PNG and Myanmar (ACTRN12616000734460) that led to changes in policy and practice in both countries.
As a co-principal investigator, he and colleagues commenced the investigation of HIV VL testing acceptability at the point of care and HIV drug resistance in Papua New Guinea in 2021. He and Ass/Prof Angela Kelly Hanku (Kirby Institute UNSW Sydney) recently secured a 3 year DFAT grant to expand HIV Viral Load testing in PNG and commence drug resistance testing of individuals who demonstrate an inability to achieve viral suppression while taking HIV antiretroviral therapy.
Dr Badman has been extensively involved in the planning and implementation of molecular point of care GeneXpert CV19 testing across 100 remote Australian sites. Part of this implementation also involved the evaluation of several viral transport media by him and his colleagues to determine if any can fully deactivate COVID 19 virus upon sample collection. Performance results from the evaluation(s) can be accessed via the publications list below and have now led to the use of a viral inactivating transport media being used across all these testing sites. Doing so reduces the need for biosafety cabinets and the risk of pathogenic transfer for test operators in laboratories and at the point of care. More recently he closed the gap on non-existant paediatric viral load testing and with colleagues introduced a new platform that now enables low impact, regular measurement of their viral load and adherence.
In conjunction with the above, and with support from the Mindaroo Foundation, Cepheid Diagnostics, The Frazer Foundation, ADB, DFAT, and key in-country partners, he has been part of the leadership team that developed a multi-million dollar consortium-led cervical elimination strategy for the Western Pacific. Vanuatu and PNG will be the starting points for this high-impact, test and treat implementation strategy which commences in 2021. To enhance this approach, Dr Badman and Professor Andrew Vallely explored options other than ThinPrep for sample collection and HPV molecular point of care testing in low and middle-income countries (publication listed below), plus HPV pooling methods to accelerate testing, save costs and interrupt cervical cancer.
See the link listed in websites and social links (left-hand column) for further details:
Research Interests
Papers共 77 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
LANCET GLOBAL HEALTHno. 4 (2024): e641-e651
Cited0Views0Bibtex
0
0
The Lancet. Global healthno. 4 (2024): e641-e651
Monica Molano,Dorothy A. Machalek, Samuel Phillips,Grace Tan, Suzanne M. Garland,David Hawkes, Prisha Balgovind, Reza Haqshenas,Steve G. Badman, John Bolnga, Josephine Gabuzzi,Zure Kombati,
Tumour Virus Research (2024): 200288-200288
Michelle J.L. Scoullar, Pele Melepia,Elizabeth Peach,Ruth Fidelis, Hadlee Supsup,Eliza M. Davidson,Philippe Boeuf,Catriona S. Bradshaw,Glenda Fehler,Priscah Hezeri,Dukduk Kabiu,Arthur Elijah,
Med (2024)
crossref(2024)
Louise M. Causer,David Anderson,Kelly Andrewartha, Paul Armstrong, David Atkinson,Steven Badman, Lisa Bastian, Catherine Carroll,Basil Donovan,Christopher Fairley,Manoji Gunathilake, Rebecca Guy,
SEXUALLY TRANSMITTED DISEASESno. 1 (2024): S151-S152
Cited0Views0Bibtex
0
0
The Lancet Regional Health. Western Pacific (2024): 101110
Cited0Views0Bibtex
0
0
The Lancet Global Healthno. 4 (2024): e641-e651
The lancet. HIVno. 4 (2023): e220-e229
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn